ORGAN-SPARING TREATMENT OF ADVANCED BLADDER-CANCER - A 10-YEAR EXPERIENCE

被引:138
|
作者
DUNST, J
SAUER, R
SCHROTT, KM
KUHN, R
WITTEKIND, C
ALTENDORFHOFMANN, A
机构
[1] UNIV ERLANGEN NURNBERG,DEPT RADIOTHERAPY,D-91054 ERLANGEN,GERMANY
[2] UNIV ERLANGEN NURNBERG,DEPT UROL,W-8520 ERLANGEN,GERMANY
[3] UNIV ERLANGEN NURNBERG,DEPT PATHOL,W-8520 ERLANGEN,GERMANY
[4] UNIV ERLANGEN NURNBERG,CTR TUMOR,W-8520 ERLANGEN,GERMANY
关键词
BLADDER CANCER; RADIOTHERAPY; TRANSURETHRAL SURGERY; CHEMOTHERAPY; BLADDER PRESERVATION;
D O I
10.1016/0360-3016(94)90003-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Radical cystectomy is considered as standard therapy for muscle-invasive bladder cancer. We present 10-year results of bladder-sparing treatment by conservative surgery and radiotherapy +/- chemotherapy. Methods and Materials: From 1982 through 1991, 245 consecutive patients, mean age 66 years, with invasive bladder cancer (T2-3 or poor prognostic T1, no distant metastases) entered a prospective protocol with the objective of bladder preservation. Treatment consisted of transurethral resection (complete, if possible) and definitive radiotherapy with 56 Gy maximum dose (50.4 Gy minimum target dose) in 28 fractions. Since 1985, 139 patients received a simultaneous chemotherapy on 5 days in the first and fifth treatment week with either 25 mg/m(2) cisplatin daily (79 patients) or 65 mg/m(2) carboplatin (60 patients). Cystectomy was performed as salvage treatment for residual or recurrent invasive disease. The median follow-up at the date of analysis (12-31-92) was 5.9 years. Results: The overall survival was 47% after 5 years and 26% after 10 years. The 5-year survival according to the initial T-category was 60% for T1 (44 patients), 64% for T2 (47 patients), 43% for T3 (127 patients), and 16% for T4 (23 patients). The most important single prognostic factor was the amount of residual tumor after TUR (5-year survival 80% after R0, 53% after R1, and 31% after R2 resection, p < 0.01). Chemotherapy increased the rate of complete remission, but had no impact on 5-year survival (52% vs. 50%). Fifty-three salvage cystectomies were performed, all without severe complications, and 192 patients (79%) maintained a normal functioning bladder. The bladder preservation rate in 5-year survivors was 83%. Conclusions: Organ-sparing treatment of advanced bladder cancer by transurethral surgery and definitive radiotherapy or radiochemotherapy is feasible and effective. The survival in this series is as good as in any comparable cystectomy series. Eighty-three percent of long-term survivors maintained their functioning bladders.
引用
收藏
页码:261 / 266
页数:6
相关论文
共 50 条
  • [31] Penile cancer: organ-sparing surgery
    Lima Pompeo, Antonio Carlos
    Zequi, Stenio de Cassio
    Feres Lima Pompeo, Alexandre Saad
    CURRENT OPINION IN UROLOGY, 2015, 25 (02) : 121 - 128
  • [32] Organ-sparing therapy for testicular cancer
    Breunig, C.
    Schrader, M.
    Schrader, A. J.
    Zengerling, F.
    UROLOGE, 2014, 53 (09): : 1302 - 1309
  • [33] Efficiency and safety of organ-sparing surgery for locally advanced kidney cancer
    Alekseeva, G. N.
    Gurina, L. I.
    Mazalov, B. V.
    Filippov, A. G.
    Volkov, M. V.
    ONKOUROLOGIYA, 2015, 11 (01): : 20 - 25
  • [34] Organ donation: a 10-year experience
    M Sharpe
    R Butler
    C Harris
    Critical Care, 9 (Suppl 1):
  • [35] Combined organ-sparing treatment for penile cancer: A case report
    Medvedev, S. V.
    Khachaturyan, A. V.
    Bulychkin, P. V.
    ONKOUROLOGIYA, 2015, 11 (02): : 96 - 98
  • [36] Organ-sparing treatment for ureteral carcinoma?
    Leitenberger, A
    Beyer, A
    Altwein, JE
    EUROPEAN UROLOGY, 1996, 29 (03) : 272 - 278
  • [37] Organ-sparing surgery for penile cancer
    Schlenker, B.
    Gratzke, C.
    Tilki, D.
    Hungerhuber, E.
    Schneede, P.
    Reich, O.
    Stief, C. G.
    Seitz, M.
    UROLOGE, 2008, 47 (07): : 803 - +
  • [38] Penile cancer: organ-sparing techniques
    Hegarty, Paul K.
    Eardley, Ian
    Heidenreich, Axel
    McDougal, W. Scott
    Minhas, Suks
    Spiess, Philippe E.
    Watkin, Nick
    Horenblas, Simon
    BJU INTERNATIONAL, 2014, 114 (06) : 799 - 805
  • [39] 10-YEAR EXPERIENCE WITH ADENOCARCINOMA OF THE BLADDER
    BENNETT, JK
    WHEATLEY, JK
    WALTON, KN
    JOURNAL OF UROLOGY, 1984, 131 (02): : 262 - 263
  • [40] Advantages of organ-sparing treatment approaches in metastatic kidney cancer
    Vitruk, Iurii
    Voylenko, Oleg
    Stakhovsky, Oleksandr
    Kononenko, Oleksii
    Pikul, Maksym
    Semko, Sofiya
    Hrechko, Bohdan
    Koshel, Denis
    Stakhovsky, Eduard
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (07) : 3131 - 3137